Wegovy and Eyesight Issues: What the Clinical Evidence Shows

What the NEJM study actually found

In July 2024, a research letter published in the New England Journal of Medicine reported a retrospective analysis of patients at a US academic medical centre. Among those with type 2 diabetes, semaglutide users had roughly four times the rate of NAION compared with people on other diabetes medicines. Among people with obesity but no diabetes, the figure was roughly seven times higher compared with non-semaglutide users. To be clear about what that means in practice: NAION is uncommon to begin with, affecting roughly 10 people per 100,000 per year in the general population, so even a several-fold increase translates to small absolute numbers. The study's authors were careful to describe this as an association, not proof that semaglutide causes the condition. Confounding factors, including baseline cardiovascular risk, were not fully adjusted for. Still, the signal was strong enough to prompt wider clinical attention, and it is the kind of finding that regulators monitor closely. If you want a closer look at the range of semaglutide issues that have attracted clinical and regulatory attention, that page brings together the broader safety picture in one place. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows patients and clinicians to report suspected adverse effects, and doing so contributes to the post-market safety picture for medicines like Wegovy.

NAION: what it is and why the optic nerve may be involved

NAION occurs when blood flow to the optic nerve is suddenly reduced, causing damage to the nerve fibres responsible for carrying visual information to the brain. It typically presents as a painless loss of vision in one eye, often noticed on waking, and can range from a small patch of reduced vision to more significant sight loss. The mechanism by which semaglutide might influence optic nerve perfusion is not yet established. One hypothesis involves rapid changes in fluid dynamics or blood pressure during significant weight loss; another points to GLP-1 receptors that are present in retinal tissue. Neither is confirmed. What the evidence from the NHS tirzepatide and semaglutide medicines pages makes clear is that sudden or unexplained visual changes are listed among the symptoms that should prompt urgent medical contact rather than waiting for a routine review. If you are already living with diabetic retinopathy, your prescriber needs to know before treatment begins, because rapid improvement in blood glucose control has a separately documented association with short-term worsening of diabetic eye disease. Our dedicated page on Wegovy and eyesight goes into more detail on what the current evidence says about this relationship and what to watch for. You can read more about how semaglutide works and its broader side-effect profile on the semaglutide overview page.

What this means before you start Wegovy

The practical upshot is straightforward. Disclose any history of eye problems, including glaucoma, optic nerve conditions, or diabetic eye disease, during your consultation. That conversation matters. At nume, a real clinician reads your consultation answers on the same day you submit them; it is not software making that call. Pre-existing conditions are weighed against the benefits and risks of treatment, and a prescriber can flag whether an ophthalmologist review is sensible before starting. For people without known eye conditions, the current evidence does not suggest that Wegovy should be avoided, but it does support vigilance. If you have specific questions about whether Wegovy can affect your eyesight, that page addresses the question directly and explains what symptoms warrant urgent attention. If at any point during treatment your vision changes suddenly, even slightly, stop and get same-day medical attention rather than waiting for your next check-in. That applies whether the change is blurring, a shadow, a patch of lost vision, or anything that feels abrupt and unexplained. There is a broader look at reported issues with Wegovy if you want to read about the wider side-effect picture alongside this one.

Ongoing monitoring and what regulators are doing

The MHRA has not, at the time of writing, issued a formal Drug Safety Update specifically on NAION and semaglutide, though the Yellow Card data feed into exactly this kind of ongoing review. The European Medicines Agency reviewed the NEJM findings and, as of mid-2024, concluded that the benefit-risk balance for semaglutide remained positive while calling for continued monitoring. Wegovy carries a Black Triangle (▼) designation in the UK, meaning the MHRA requires additional surveillance precisely because it is a relatively new medicine. That monitoring infrastructure exists to catch signals like the NAION association early. If you are weighing up your options and want to understand the difference between Wegovy and other licensed treatments, the Wegovy treatment overview sets out the full picture. For questions about cost context and what a private prescription service includes, the weight-loss treatments page explains what is covered in a single transparent price, with no subscription. Our clinical team is available to answer questions through the consultation if any of this raises concerns specific to your situation. Speak to our prescribers before starting, and keep them informed if anything changes after you do.